Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Other Non Operating Income (2019 - 2023)

C4 Therapeutics' Other Non Operating Income history spans 3 years, with the latest figure at -$621000.0 for Q3 2023.

  • For Q3 2023, Other Non Operating Income changed N/A year-over-year to -$621000.0; the TTM value through Dec 2024 reached -$621000.0, changed 0.0%, while the annual FY2023 figure was -$621000.0, N/A changed from the prior year.
  • Other Non Operating Income reached -$621000.0 in Q3 2023 per CCCC's latest filing, down from $43000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $43000.0 in Q3 2020 to a low of -$621000.0 in Q3 2023.
  • Average Other Non Operating Income over 3 years is -$193000.0, with a median of -$1000.0 recorded in 2019.
  • The largest YoY upside for Other Non Operating Income was 4400.0% in 2020 against a maximum downside of 4400.0% in 2020.
  • A 3-year view of Other Non Operating Income shows it stood at -$1000.0 in 2019, then soared by 4400.0% to $43000.0 in 2020, then crashed by 1544.19% to -$621000.0 in 2023.
  • Per Business Quant, the three most recent readings for CCCC's Other Non Operating Income are -$621000.0 (Q3 2023), $43000.0 (Q3 2020), and -$1000.0 (Q3 2019).